Investigational Drug Information for LGX818
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug LGX818?
LGX818 is an investigational drug.
There have been 31 clinical trials for LGX818.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 21st 2020.
The most common disease conditions in clinical trials are Melanoma, Colorectal Neoplasms, and Neoplasms. The leading clinical trial sponsors are Array BioPharma, Pfizer, and National Cancer Institute (NCI).
There are two hundred and thirty US patents protecting this investigational drug and two international patents.
Summary for LGX818
| US Patents | 230 |
| International Patents | 2,364 |
| US Patent Applications | 914 |
| WIPO Patent Applications | 848 |
| Japanese Patent Applications | 299 |
| Clinical Trial Progress | Phase 2 (2020-12-21) |
| Vendors | 43 |
Recent Clinical Trials for LGX818
| Title | Sponsor | Phase |
|---|---|---|
| Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation | National Cancer Institute (NCI) | Phase 2 |
| BRAF V600E-mutant and MSI-H Metastatic Colorectal Cancer Study of Encorafenib Taken With Cetuximab Plus Pembrolizumab Compared to Pembrolizumab Alone | Eli Lilly and Company | Phase 2 |
| BRAF V600E-mutant and MSI-H Metastatic Colorectal Cancer Study of Encorafenib Taken With Cetuximab Plus Pembrolizumab Compared to Pembrolizumab Alone | Merck KGaA, Darmstadt, Germany | Phase 2 |
Clinical Trial Summary for LGX818
Top disease conditions for LGX818
Top clinical trial sponsors for LGX818
US Patents for LGX818
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| LGX818 | See Plans and Pricing | Compounds and compositions as protein kinase inhibitors | Array BioPharma Inc. (Boulder, CO) | See Plans and Pricing |
| LGX818 | See Plans and Pricing | Small molecule HSP70 inhibitors | The Trustees of the University of Pennsylvania (Philadelphia, PA) The Wistar Institute of Anatomy and Biology (Philadelphia, PA) | See Plans and Pricing |
| LGX818 | See Plans and Pricing | Compounds and compositions as inhibitors of MEK | Novartis AG (Basel, CH) | See Plans and Pricing |
| LGX818 | See Plans and Pricing | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (Knoxville, TN) | See Plans and Pricing |
| LGX818 | See Plans and Pricing | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof | Samumed, LLC (San Diego, CA) | See Plans and Pricing |
| LGX818 | See Plans and Pricing | Aerosol pirfenidone and pyridone analog compounds and uses thereof | AVALYN PHARMA INC. (Seattle, CA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for LGX818
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| LGX818 | Argentina | AR077975 | 2029-08-28 | See Plans and Pricing |
| LGX818 | Australia | AU2010286569 | 2029-08-28 | See Plans and Pricing |
| LGX818 | Brazil | BR112012004453 | 2029-08-28 | See Plans and Pricing |
| LGX818 | Canada | CA2771775 | 2029-08-28 | See Plans and Pricing |
| LGX818 | Chile | CL2012000340 | 2029-08-28 | See Plans and Pricing |
| LGX818 | China | CN102725283 | 2029-08-28 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
